These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
526 related items for PubMed ID: 19346379
1. Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient. Pandey BD, Pandey K, Kaneko O, Yanagi T, Hirayama K. Am J Trop Med Hyg; 2009 Apr; 80(4):580-2. PubMed ID: 19346379 [Abstract] [Full Text] [Related]
2. Oral miltefosine for Indian visceral leishmaniasis. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J. N Engl J Med; 2002 Nov 28; 347(22):1739-46. PubMed ID: 12456849 [Abstract] [Full Text] [Related]
3. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis. Das VN, Pandey K, Verma N, Lal CS, Bimal S, Topno RK, Singh D, Siddiqui NA, Verma RB, Das P. Am J Trop Med Hyg; 2009 Mar 28; 80(3):336-8. PubMed ID: 19270277 [Abstract] [Full Text] [Related]
8. Relapse of new world diffuse cutaneous leishmaniasis caused by Leishmania (Leishmania) mexicana after miltefosine treatment. Calvopina M, Gomez EA, Sindermann H, Cooper PJ, Hashiguchi Y. Am J Trop Med Hyg; 2006 Dec 15; 75(6):1074-7. PubMed ID: 17172368 [Abstract] [Full Text] [Related]
9. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India. Srivastava S, Mishra J, Gupta AK, Singh A, Shankar P, Singh S. Parasit Vectors; 2017 Jan 31; 10(1):49. PubMed ID: 28137296 [Abstract] [Full Text] [Related]
11. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine. Sangraula H, Sharma KK, Rijal S, Dwivedi S, Koirala S. J Assoc Physicians India; 2003 Jul 31; 51():686-90. PubMed ID: 14621038 [Abstract] [Full Text] [Related]
12. Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. Zerpa O, Ulrich M, Blanco B, Polegre M, Avila A, Matos N, Mendoza I, Pratlong F, Ravel C, Convit J. Br J Dermatol; 2007 Jun 31; 156(6):1328-35. PubMed ID: 17441955 [Abstract] [Full Text] [Related]
15. [Miltefosine: a new remedy for leishmaniasis]. Dorlo TP, Eggelte TA, Beijnen JH, de Vries PJ. Ned Tijdschr Geneeskd; 2006 Dec 09; 150(49):2697-701. PubMed ID: 17194005 [Abstract] [Full Text] [Related]
17. Adherence to miltefosine treatment for visceral leishmaniasis under routine conditions in Nepal. Uranw S, Ostyn B, Dorlo TP, Hasker E, Dujardin B, Dujardin JC, Rijal S, Boelaert M. Trop Med Int Health; 2013 Feb 09; 18(2):179-87. PubMed ID: 23199340 [Abstract] [Full Text] [Related]
18. Use of miltefosine in the treatment of visceral leishmaniasis in children at a tertiary care hospital of Karachi. Humayun KN, Saleem T, Khalid U, Jehan F, Soofi S. J Pak Med Assoc; 2010 Jun 09; 60(6):489-91. PubMed ID: 20527651 [Abstract] [Full Text] [Related]
19. Case report: Expansion of visceral leishmaniasis to the western hilly part of Nepal. Pandey BD, Pun SB, Kaneko O, Pandey K, Hirayama K. Am J Trop Med Hyg; 2011 Jan 09; 84(1):107-8. PubMed ID: 21212211 [Abstract] [Full Text] [Related]
20. [An adult case of visceral leishmaniasis in a province of Black-Sea region, Turkey]. Oztoprak N, Aydemir H, Pişkin N, Seremet Keskin A, Araslı M, Gökmen A, Celebi G, Külekçi Uğur A, Taylan Özkan A. Mikrobiyol Bul; 2010 Oct 09; 44(4):671-7. PubMed ID: 21063981 [Abstract] [Full Text] [Related] Page: [Next] [New Search]